Table 4.
Effects of CMR-RVpGLS on 5-year major adverse cardiac events in patients with stage C or D heart failure with non-ischaemic dilated cardiomyopathy in each subgroup by multivariable Cox model
| CMR-RVpGLS | HR (95% CI) | P value | P for interaction |
| Age (years) | 0.522 | ||
| ≤56 | 1.07 (0.92 to 1.25) | 0.353 | |
| >56 | 1.25 (1.00 to 1.57) | 0.047 | |
| Sex | 0.359 | ||
| Female | 0.97 (0.78 to 1.20) | 0.763 | |
| Male | 1.19 (1.03 to 1.38) | 0.017 | |
| BMI | 0.441 | ||
| ≤26 | 1.12 (0.98 to 1.29) | 0.089 | |
| >26 | 1.22 (0.93 to 1.59) | 0.153 | |
| Hypertension | 0.144 | ||
| No | 1.08 (0.94 to 1.25) | 0.253 | |
| Yes | 1.31 (0.99 to 1.73) | 0.058 | |
| Diabetes mellitus | 0.240 | ||
| No | 1.21 (1.03 to 1.42) | 0.018 | |
| Yes | 1.02 (0.86 to 1.22) | 0.784 | |
| LBBB on EKG | 0.279 | ||
| No | 1.11 (0.97 to 1.27) | 0.118 | |
| Yes | 1.27 (0.92 to 1.75) | 0.142 |
*Adjusted for age, sex, BMI, hypertension, diabetes mellitus, LBBB on EKG and CMR LVLGE except the subgroup variable.
BMI, body mass index; CMR, cardiac magnetic resonance; LBBB, left bundle branch block; LVLGE, left ventricular late gadolinium enhancement; RVpGLS, right ventricular peak global longitudinal strain.